Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-04-26
2010-02-02
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S238000
Reexamination Certificate
active
07655657
ABSTRACT:
Compounds of formula (II):known as: 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1-H-indole salt with (2R, 3R)-2,3-dihydroxybutanedioic acid (1:1).
REFERENCES:
patent: 5385912 (1995-01-01), Neuenshwander et al.
patent: 2003/0199511 (2003-10-01), Li et al.
patent: 2005/0137184 (2005-06-01), Ji et al.
patent: 2005/0137204 (2005-06-01), Ji et al.
patent: 2005/0245531 (2005-11-01), Ji et al.
patent: 2006/0211686 (2006-09-01), Kohlhaas et al.
patent: 0458214 (1991-05-01), None
patent: 0456519 (1994-07-01), None
patent: WO94/18201 (1994-08-01), None
patent: WO92/15579 (1992-09-01), None
patent: WO95/03302 (1995-02-01), None
patent: WO95/31458 (1995-11-01), None
patent: WO96/12711 (1996-05-01), None
patent: WO97/17956 (1997-05-01), None
patent: WO97/17962 (1997-05-01), None
patent: WO97/20819 (1997-06-01), None
patent: WO97/17955 (1997-11-01), None
patent: WO99/10339 (1999-03-01), None
patent: WO00/71520 (2000-11-01), None
patent: 2004/016608 (2004-02-01), None
patent: 2004/022556 (2004-03-01), None
patent: 2006065233 (2006-06-01), None
patent: WO2006/065233 (2006-06-01), None
Galligan et al., Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society, (Dec. 2002) vol. 14, No. 6, pp. 611-623. Ref: 119).
Adler et al, “Schizophrenia, sensory gating, and nicotinic receptors,” Schizophrenia Bulletin 24(2):189-202 (1998).
Cordero-Erausquin et al., “Tonic nicotinic modulation of serotoninergic transmission in the spinal cord,” PNAS 98(5):2803-2807 (2001).
Friedman et al., “A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia,” Biol. Psychiatry 51:349-357 (2002).
Heeschen et al., “Nicotine stimulates angiogenesis and promotes tumor growth and athersclerosis,” Nature Medicine 7(7):833-839 (2001).
Heeschen et al., “A novel angiogenic pathway mediated by non-neuronal nicotinic acetycholine receptors,” Journal of Clinical Investigation 110(4):527-536 (2002).
Jonnala et al., “Relationship between the increased cell surface α7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists,” Journal of Neuroscience Research 66:565-572 (2001).
Kihara et al., “α7 Nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A β-amyloid-induced neurotoxicity,” Journal of Biological Chemistry 276(17):13541-13546 (2001).
Leonard et al., “Smoking and schizophrenia: abnormal nicotinic receptor expression,” European Journal of Pharmacology 393:237-242 (2000).
Levin, “Nicotinic receptor subtypes and cognitive function,” J. Neurobiol. 53:633-640 (2002).
Liu et al., “β-Amyloid peptide blocks the response of α7-containing nicotinic receptors on hippocampal neurons,” PNAS 98(8):4734-4739 (2001).
Rowley et al., “Current and novel approaches to the drug treatment of schizophrenia,” Journal of Medicinal Chemistry 44(4):477-501 (2001).
Shimohama et al., “Nicotinic α7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage,” Brain Research 779:359-363 (1998).
Son et al., “Evidence suggesting that the mouse sperm acrosome reaction initiated by the zona pellucida involves an α7 nicotinic acetylcholine receptor,” Biology of Reproduction 68:1348-1353 (2003).
Stevens et al., “Selective α7-nicotinic agonists normalize inhibition of auditory response in DBA mice,” Psychopharmacology 136:320-327 (1998).
Torii et al., “A versatile cycloaddition for the generation of pyrrolidine derivativesviaC-N-C 1,3-dipoles,” Chemistry Letters 747-748 (1996).
Wang et al., “Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation,” Nature 421:384-388 (2003).
Holladay et al., “Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery,” J. Med. Chem., 40(26):4169-4194 (1997).
Brown et al., “Synthesis and Activity of a Novel Series of 3-Biarylquinuclidine Squalene Synthase Inhibitor,” J. Med. Chem., 39(15): 2971-2979 (1996).
Christesen Alan
Ji Jianguo
Law Devalina
Murphey David B.
Pal Agnes
Abbott Laboratories
Chen Portia
Rahmani Niloofar
Seaman D. Margaret
LandOfFree
Fused bicycloheterocycle substituted quinuclidine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused bicycloheterocycle substituted quinuclidine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused bicycloheterocycle substituted quinuclidine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4214947